The labelling and advertising of infant formula products should be Not applicable to this Application Not consistent with the World Health Organization International Code of applicable Marketing of Breast Milk Substitutes as implemented in Australia and New Zealand The labelling and advertising of infant formula products should not Not applicable to this Application. Not represent those products as an equivalent to, or better food than, applicable breast milk The labelling and advertising of infant formula products should provide Not applicable to this Application. Not information on the appropriate and safe use of those products applicable The Authority should: The appropriate common, descriptive or generic name of the Yes ensure that the prohibitions and restrictions on nutrient content, fructans added to the formula must be declared on a label of health, therapeutic, and prophylactic claims in the Food an infant formula product in the same manner as inulin-derived Standards Code are clear and effective for infant formula substances. The current prohibition on nutrition claims and health products; and claims will also apply to short chain FOSsucrose. consider whether the current labelling regime is leading to consumers being misled about the quality or effectiveness of an infant formula product. Expert Group FSANZ should consider establishing an independent scientific expert FSANZ has sought advice from its independent Infant and Child Yes group that may provide advice prior to pre-market assessment, based on Health Scientific Advisory Group on the risk assessment. scientific criteria established by the Authority, on whether: a substance proposed to be added to infant formula products has a history of safe use in infant formula or follow-on formula in Australia and New Zealand; and there is evidence available that the substance has a substantiated beneficial role in the normal growth and development of infants or children. Relevant international agreements The regulation of infant formula products in Australia and New Zealand FSANZ has taken account of the relevant World Trade Yes should be consistent Organization agreements, Codex standards and guidelines. Short to the greatest extent possible with: chain FOSsucrose is permitted and used in some infant formula products sold overseas. relevant World Health Organization agreements; and relevant World Trade Organization agreements, Codex standards and guidelines
The labelling and advertising of infant formula products should be consistent with the World Health Organization International Code of Marketing of Breast Milk Substitutes as implemented in Australia and New Zealand Not applicable to this Application Not applicable The labelling and advertising of infant formula products should not represent those products as an equivalent to, or better food than, breast milk Not applicable to this Application. Not applicable The labelling and advertising of infant formula products should provide information on the appropriate and safe use of those products Not applicable to this Application. Not applicable The Authority should: ensure that the prohibitions and restrictions on nutrient content, health, therapeutic, and prophylactic claims in the Food Standards Code are clear and effective for infant formula products; and consider whether the current labelling regime is leading to consumers being misled about the quality or effectiveness of an infant formula product. The appropriate common, descriptive or generic name of the fructans added to the formula must be declared on a label of an infant formula product in the same manner as inulin-derived substances. The current prohibition on nutrition claims and health claims will also apply to short chain FOSsucrose. Yes Expert Group FSANZ should consider establishing an independent scientific expert group that may provide advice prior to pre-market assessment, based on scientific criteria established by the Authority, on whether: a substance proposed to be added to infant formula products has a history of safe use in infant formula or follow-on formula in Australia and New Zealand; and there is evidence available that the substance has a substantiated beneficial role in the normal growth and development of infants or children. FSANZ has sought advice from its independent Infant and Child Health Scientific Advisory Group on the risk assessment. Yes Relevant international agreements The regulation of infant formula products in Australia and New Zealand should be consistent to the greatest extent possible with: relevant World Health Organization agreements; and relevant World Trade Organization agreements, Codex standards and guidelines FSANZ has taken account of the relevant World Trade Organization agreements, Codex standards and guidelines. Short chain FOSsucrose is permitted and used in some infant formula products sold overseas. Yes